参考文献

1.Mural H.Myasthenia gravis:past，present，and future.Rinsho Shinkeigaku，2014，54（12）:947-949.

2.Conti-Fine BM，Milani M，Kaminski HJ.Myasthenia gravis:past，present，and future.J Clin Invest，2006，116（11）:2843-2854.

3.Jani-Acsadi A，Lisak RP.Myasthenic crisis:Guidelines for prevention and treatment.J Neurol Sci，2007，261（1）:127-133.

4.彭丹涛，许贤豪，佘子瑜.新斯的明试验改良结果判定法研究.中国神经免疫学和神经病学杂志，2007，14:1-3.

5.Kerty El，Elsais A，Argov Z，et al.EFNS/ENS Guidelines for the treatment of ocular myasthenia.Eur J Neurol，2014，21（5）:687-693.

6.中华医学会神经病学分会神经免疫学组，中国免疫学会神经免疫学分会.中国重症肌无力诊断和治疗指南.中华神经科杂志，2015，48（11）:368-372.(https://www.daowen.com)

7.Meyer DM，Herbert MA，Sobhani NC，et al.Comparative clinical outcomes of thymectomy for myasthenia gravis performed by extended transsternal and minimally invasive approaches.Ann Thorac Surg，2009，87（2）:385-390.

8.Skeie GO，Apostolski S，Evoli A，et al.Guidelines for treatment of autoimmune neuromuscular transmission disorders.Eur J Neurol，2010，17（7）:893-902.

9.Jani Acsadi A，Lisak RP，et al.Myasthenia gravis.Curr Treat Options Neurol，2010，12（3）:231-243.

10.Kosmidis ML，Dalakas MC，et al.Practical considerations on the use of rituximab in autoimmune neurological disorders.Ther Adv Neurol Disord，2010，3（2）:93-105.

11.Cortese I，Chaudhry V，So YT，et al.Evidence-based guideline update:Plasmapheresis in neurologic disorders:report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.Neurology，2011，76（3）:294-300.

12.Evoli A，Antonini G，Antozzi C，et al.Italian recommendations for the diagnosis and treatment of myasthenia gravis.Neurol Sci，2019，40（6）:1111-1124.